



January 13, 2023

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Announcement of approval of additional indication of Ranibizumab BS
(Excerpt from Japanese version)

Tokyo, January 13, 2023 – Kidswell Bio Corporation (KWB) is delighted to announce that Senju Pharmaceutical Co., Ltd. received an approval of partial modification of pharmaceutical manufacturing approval for diabetic macular edema as additional indication of Ranibizumab BS (Project name: GBS-007) in addition to age-related macular degeneration and choroidal neovascularization due to pathologic myopia.

There is no impact on KWB's business and financial situation. This expansion of indication of GBS-007 will enhance KWB's corporate value by strengthening the biosimilar business.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, stem cell from exfoliated deciduous teeth, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com